semaglutide long acting (AdoGel Sema) / Adocia - LARVOL DELTA

AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations (ADA 2026) - "These results indicate that AdoXLong Sema offers an effective strategy to extend the half-life and duration of action of semaglutide, potentially enabling once-monthly administration in humans."

Late-breaking abstract • Metabolic Disorders

STABLE CO-FORMULATION OF CAGRILINTIDE AND SEMAGLUTIDE WITH THE BIOCHAPERONE® PLATFORM FOR MULTI-DOSE PEN INJECTORS: ENABLING FLEXIBLE DOSING IN OBESITY TREATMENT (ATTD 2026) - "BC-CagriSema allows multiple-dose injections of Cagrilintide and Semaglutide. This innovation could enhance clinical applicability through flexible titration and long-term treatment adherence in obesity and diabetes care."

Cardiovascular • Diabetes • Genetic Disorders • Obesity

Fourth quarter 2024 Highlights (Businesswire) - "AdoGel's unique technology could enable monthly or even quarterly injections. New preclinical results have been selected for a poster presentation at the ATTD 2025 conference (18th International Conference on Advanced Technologies & Treatments for Diabetes, 19-22 March, 2025, Amsterdam, The Netherlands) and for an oral presentation at the SFD 2025 congress (Congress of the Société Francophone du Diabète, April 1-4, 2025, Paris, France)."

Preclinical • Diabetes